Relapsed Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase 2 Trial Evaluating the Efficacy of Flotetuzumab (MGD006) for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional therapeutic efficacy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01961765 -
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Not yet recruiting |
NCT05362942 -
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
|
Phase 2 | |
| Terminated |
NCT02109627 -
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
|
Phase 1 | |
| Withdrawn |
NCT04354025 -
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
|
Phase 2 | |
| Withdrawn |
NCT04893915 -
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
|
Phase 2 | |
| Recruiting |
NCT04891757 -
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04797767 -
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
|
Phase 1 | |
| Completed |
NCT05456048 -
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
|
||
| Completed |
NCT02996474 -
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05028751 -
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06017258 -
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
|
Phase 1 | |
| Not yet recruiting |
NCT06177067 -
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
|
Phase 1 |